Page 64 - 南京医科大学学报自然科学版
P. 64
第43卷第5期
·646 · 南 京 医 科 大 学 学 报 2023年5月
[10] 王梦玮,徐天蔚,王朝霞. PD⁃1/PD⁃L1免疫检查点抑制 and anti⁃tumor efficacy of immune checkpoint inhibitors
剂在肺癌临床研究中的进展[J]. 南京医科大学学报 [J]. J Immunother Cancer,2019,7(1):306
(自然科学版),2021,41(7):1084-1094 [25] MAHER V E,FERNANDES L L,WEINSTOCK C,et al.
[11] BORGHAEI H,GETTINGER S,VOKES E E,et al. Five⁃ Analysis of the association between adverse events and
year outcomes from the randomized,phase Ⅲ trials outcome in patients receiving a programmed death protein
CheckMate 017 and 057:nivolumab versus docetaxel in 1 or programmed death ligand 1 antibody[J]. J Clin On⁃
previously treated non⁃small⁃cell lung cancer[J]. J Clin col,2019,37(30):2730-2737
Oncol,2021,39(7):723-733 [26] SHANKAR B,ZHANG J,NAQASH A R,et al. Multisys⁃
[12] WEIR H K,THOMPSON T D,SOMAN A,et al. The past, tem immune ⁃ related adverse events associated with im⁃
present,and future of cancer incidence in the United mune checkpoint inhibitors for treatment of non ⁃ small
States:1975 through 2020[J]. Cancer,2015,121(11): cell lung cancer[J]. JAMA Oncol,2020,6(12):1952-
1827-1837 1956
[13] XIA C,DONG X,LI H,et al. Cancer statistics in China [27] HODI F S,O’DAY S J,MCDERMOTT D F,et al. Im⁃
and United States,2022:profiles,trends,and determi⁃ proved survival with ipilimumab in patients with metastat⁃
nants[J]. Chin Med J(Engl),2022,135(5):584-590 ic melanoma[J]. N Engl J Med,2010,363(8):711-723
[14] HELISSEY C,VICIER C,CHAMPIAT S. The develop⁃ [28] KWON E D,DRAKE C G,SCHER H I,et al. Ipilimumab
ment of immunotherapy in older adults:new treatments, versus placebo after radiotherapy in patients with meta⁃
new toxicities?[J]. J Geriatr Oncol,2016,7(5):325-333 static castration ⁃ resistant prostate cancer that had pro⁃
[15] KENDAL W S. Dying with cancer:the influence of age, gressed after docetaxel chemotherapy(CA184 ⁃ 043):a
comorbidity,and cancer site[J]. Cancer,2008,112(6): multicentre,randomised,double⁃blind,phase 3 trial[J].
1354-1362 Lancet Oncol,2014,15(7):700-712
[16] GORONZY J J,WEYAND C M. Understanding immunose⁃ [29] EGGERMONT A M,CHIARION⁃SILENI V,GROB J J,et
nescence to improve responses to vaccines[J]. Nat Immu⁃ al. Adjuvant ipilimumab versus placebo after complete re⁃
nol,2013,14(5):428-436 section of high⁃risk stage Ⅲ melanoma(EORTC 18071):
[17] SOLANA R,TARAZONA R,GAYOSO I,et al. Innate im⁃ a randomised,double⁃blind,phase 3 trial[J]. Lancet On⁃
munosenescence:effect of aging on cells and receptors of col,2015,16(5):522-530
the innate immune system in humans[J]. Semin Immu⁃ [30] SPAIN L,DIEM S,LARKIN J. Management of toxicities
nol,2012,24(5):331-341 of immune checkpoint inhibitors[J]. Cancer Treat Rev,
[18] NIKOLICH⁃ZUGICH J. The twilight of immunity:emerg⁃ 2016,44:51-60
ing concepts in aging of the immune system[J]. Nat Im⁃ [31] PAWELEC G. Age and immunity:what is“immunosenes⁃
munol,2018,19(1):10-19 cence”?[J]. Exp Gerontol,2018,105:4-9
[19] PALMER S,ALBERGANTE L,BLACKBURN C C,et al. [32] PAWELEC G,BRONIKOWSKI A,CUNNANE S C,et al.
Thymic involution and rising disease incidence with age The conundrum of human immune system“senescence”
[J]. Proc Natl Acad Sci U S A,2018,115(8):1883-1888 [J]. Mech Ageing Dev,2020,192:111357
[20] SEDRAK M S,FREEDMAN R A,COHEN H J,et al. Old⁃ [33] THOMAS R,WANG W,SU D M. Contributions of age⁃re⁃
er adult participation in cancer clinical trials:a systemat⁃ lated thymic involution to immunosenescence and inflam⁃
ic review of barriers and interventions[J]. CA Cancer J maging[J]. Immun Ageing,2020,17:2
Clin,2021,71(1):78-92 [34] ACCARDI G,CARUSO C. Immune⁃inflammatory respons⁃
[21] HURRIA A,DALE W,MOONEY M,et al. Designing ther⁃ es in the elderly:an update[J]. Immun Ageing,2018,15:
apeutic clinical trials for older and frail adults with can⁃ 11
cer:U13 conference recommendations[J]. J Clin Oncol, [35] PINTI M,APPAY V,CAMPISI J,et al. Aging of the im⁃
2014,32(24):2587-2594 mune system:focus on inflammation and vaccination[J].
[22] 黎艳娜,王艺桥. 我国老年人慢性病共病现状及模式研 Eur J Immunol,2016,46(10):2286-2301
究[J]. 中国全科医学,2021,24(31):3955-3962 [36] JUNE C H,WARSHAUER J T,BLUESTONE J A. Is au⁃
[23] HELLMANN M D,PAZ⁃ARES L,BERNABE CARO R, toimmunity the Achilles’heel of cancer immunotherapy?
et al. Nivolumab plus ipilimumab in advanced non⁃small⁃ [J]. Nat Med,2017,23(5):540-547
cell lung cancer[J]. N Engl J Med,2019,381(21): [37] POSTOW M A,SIDLOW R,HELLMANN M D. Immune⁃
2020-2031 related adverse events associated with immune check⁃
[24] DAS S,JOHNSON D B. Immune⁃related adverse events point blockade[J]. N Engl J Med,2018,378(2):158-168